The purpose of this phase III study is to determine the efficacy of difluprednate in the treatment of inflammation following ocular surgery.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
219
Comprehensive Eye Care
Washington, Missouri, United States
Anterior Chamber Cell Grade of "0" on Day 8 (Difluprednate QID vs Placebo).
Measured on a 0 to 4 scale: "0" is ≤ 1 cell; "1" is 2-10 cells; "2" is 11-20 cells; "3" is 21-50 cells; "4" is \> 50 cells.
Time frame: Day 8 (QID)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.